An In Vitro Study Simulating Prophylactic Anticoagulation in Haemophilia A and B
eJHaem · 2026-12 · 7 (6)
DOI: 10.1002/jha2.70314 ↗Kurz gefasst
Fachartikel in der Zeitschrift eJHaem, online erschienen am 30.10.2026. Verfasst von Nicoletta Riva und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology Faculty of Medicine and Surgery University of Malta Msida Malta. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Patients with haemophilia A (HA) and haemophilia B (HB) are at increased bleeding risk. A recent guidance document suggests considering pharmacological thromboprophylaxis on a case‐by‐case basis in these patients undergoing surgery at high‐risk of venous thromboembolism. This study aimed to assess the effect of prophylactic doses of three anticoagulants (enoxaparin, rivaroxaban and unfractionated heparin [UFH]) on in vitro models of HA and HB.
Methods
FVIII‐ and FIX‐deficient plasma were spiked with FVIII and FIX concentrates to mimic severe, moderate and mild HA (FVIII concentrations < 1%, 1.2% and 17.0%, respectively) and HB (FIX concentrations < 1%, 3.9% and 22.9%, respectively). Each pool was spiked with enoxaparin (concentration range 0.3–0.4 IU/mL), rivaroxaban (50–100 ng/mL) and UFH (0.2–0.3 IU/mL). The following assays were performed: prothrombin time (PT), activated partial thromboplastin time (APTT) and thrombin generation (using the semi‐automated fluorogenic calibrated automated thrombin generation assay [CAT]).
Results
The PT was not significantly affected by the anticoagulants. A significant prolongation of the APTT was observed; UFH showed the greatest increase, followed by rivaroxaban and enoxaparin. All anticoagulants impacted on the CAT curves. UFH showed the greatest reduction of the endogenous thrombin potential; rivaroxaban showed the greatest increase of lag time and time to peak. Peak thrombin and velocity index were similarly reduced by rivaroxaban and UFH, whereas enoxaparin was associated with smaller changes in all parameters.
Conclusion
A significant effect of three prophylactic anticoagulants was observed in factor‐deficient plasmas. This study provides further insight into this topic and supports the concept of an individualised approach to haemophilia patients. Trial Registration : The authors have confirmed clinical trial registration is not needed for this submission
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology Faculty of Medicine and Surgery University of Malta Msida Malta.
- Coagulation Laboratory Department of Pathology Mater Dei Hospital Msida Malta.
- Sheffield Haemophilia and Thrombosis Centre University of Sheffield Sheffield UK.
- Department of Applied Biomedical Science Faculty of Health Sciences University of Malta Msida Malta.
- National Blood Transfusion Service Pietà Malta.
- Department of Statistics & Operations Research Faculty of Science University of Malta Msida Malta.
ORCID-Profile: Nicoletta Riva, Kevin Vella, Kieron Hickey, Nigel Debattista, Carmel Grima, Denise Borg-Aquilina, Liberato Camilleri, Jiong Jiong Guo, Alexander Gatt
Zitieren
APA
Riva, N., Vella, K., Hickey, K., Debattista, N., Grima, C., Borg-Aquilina, D., Camilleri, L., Guo, J. J., & Gatt, A. (2026). An In Vitro Study Simulating Prophylactic Anticoagulation in Haemophilia A and B. eJHaem, 7(6). https://doi.org/10.1002/jha2.70314
Vancouver
Riva N, Vella K, Hickey K, Debattista N, Grima C, Borg-Aquilina D, et al. An In Vitro Study Simulating Prophylactic Anticoagulation in Haemophilia A and B. eJHaem. 2026;7(6). doi:10.1002/jha2.70314
BibTeX
@article{Riva2026,
author = {Riva, Nicoletta and Vella, Kevin and Hickey, Kieron and Debattista, Nigel and Grima, Carmel and Borg-Aquilina, Denise and Camilleri, Liberato and Guo, Jiong Jiong and Gatt, Alexander},
title = {An In Vitro Study Simulating Prophylactic Anticoagulation in Haemophilia A and B},
journal = {eJHaem},
year = {2026},
volume = {7},
number = {6},
doi = {10.1002/jha2.70314}
}
EUVIMED